Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session - NETs and endocrine tumours

LBA41 - Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC)

Date

21 Sep 2021

Session

Proffered Paper session - NETs and endocrine tumours

Presenters

Thomas Walter

Citation

Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741

Authors

N. Girard1, J. Mazieres2, J. Otto3, H. Lena4, C. Lepage5, T. Egenod6, D. Smith7, J. Madelaine8, L. Gérinière9, F. El Hajbi10, A. Ferru11, C. Clément-Duchêne12, A. Madroszyk13, J. Desrame14, F. Morin15, A. Langlais15, P. Michel16, C. Louvet17, V. Westeel18, T. Walter19

Author affiliations

  • 1 Thorax Institute, Institut Curie, 75005 - Paris/FR
  • 2 Thoracic Oncology Department, Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, 31059 - Toulouse/FR
  • 3 Oncology, Centre Antoine Lacassagne, 6100 - Nice/FR
  • 4 Pneumology, Hôpital Pontchaillou, 35033 - Rennes/FR
  • 5 Hepato Gastroenterology And Digestive Oncology, CHU Dijon, 21079 - Dijon/FR
  • 6 Thoracic Oncology Department, CHU Limoges - Hopital Dupuytren, 87042 - Limoges/FR
  • 7 Hepato Gastroenterology And Digestive Oncology, Hopital Haut Leveque, 33000 - Pessac/FR
  • 8 Pneumology Department, CHU de Caen - Hopital Cote de Nacre, 14033 - Caen/FR
  • 9 Pneumology, HCL - Centre Hospitalier Lyon Sud, 69310 - PIERRE-BENITE/FR
  • 10 Oncology, Centre Oscar Lambret, 59020 - Lille/FR
  • 11 Oncology, CHU Poitiers, Jean Bernard Hôpital, 86021 - Poitiers/FR
  • 12 Oncology, Institut de Cancérologie de Lorraine, 54511 - Vandœuvre-lès-Nancy/FR
  • 13 Medical Oncology, Institute Paoli Calmettes, 13273 - Marseille Cedex /FR
  • 14 Oncology, Hôpital privé Jean Mermoz, 69373 - Lyon/FR
  • 15 Clinical Research Unit, French Cooperative Thoracic Intergroup, 75009 - Paris/FR
  • 16 Hepato-gastroenterology, Rouen University Hospital, 76031 - Rouen/FR
  • 17 Oncology, Institute Mutualiste Montsouris, 75014 - Paris/FR
  • 18 Pneumology, CHRU Besancon - Hopital Jean Minjoz, 25030 - Besançon/FR
  • 19 Gastroenterology And Digestive Oncology, HCL - Hopital Edouard Herriot, 69003 - lyon/FR
More

Resources

Login to access the resources on OncologyPRO.

Abstract LBA41

Background

Neuroendocrine Carcinomas (NECs) are a distinct family of poorly differentiated morphology, sharing molecular, clinical and outcome characteristics. No standard-of-care exists after the failure of first-line platinum-based chemotherapy (CT) regimens. Nivo±ipi has been reported to provide survival benefit versus standard CT in metastatic solid cancers.

Methods

GCO-001 NIPINEC is a multicenter, non-comparative, randomized (1:1) phase 2 trial with a two-step design (early stopping for futility after 50% of accrual). Main inclusion criteria were histologically proven NEC (large- and small-cell for gastroenteropancreatic (GEP) NECs, and large-cell for lung NECs), in 2nd or 3rd line refractory to platinum-based CT, and PS 0-2. Patients received nivo 3 mg/kg q2w ± ipi 1 mg/kg q6w, for 2 years or until progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) at 8 weeks assessed by investigators (power of 90%, alpha risk at 5% two-sided). Other endpoints included progression-free survival (PFS), overall survival (OS) and safety. NCT number: NCT03591731.

Results

From Dec 2018 to Mar 2021, 185 patients (93 GEP and 92 lung) were enrolled in 50 centers. Median age was 64.4 years (range 26.4–87.1), 71% males, 70% smokers, 91% with ECOG PS 0 or 1, 24% with asymptomatic brain metastases. 170 (92%) patients were evaluable for the primary endpoint. ORR at 8 weeks was 7.2% (95%CI [2.7-15.1]) with nivo and 14.9% (95%CI [8.2-24.2]) with nivo+ipi. Median PFS was 1.8 months (95%CI [1.7-2.0]) with nivo and 1.9 months (95%CI [1.6-2.1]) with nivo+ipi. Median OS was 7.2 months (95%CI [3.7-14.1]) with nivo and 5.8 months (95%CI [3.3-7.6]) with nivo+ipi. 3 patients (3.5%) and 7 patients (8.9%) experienced treatment discontinuation because of toxicity with nivo and nivo+ipi respectively. 2 treatment-related deaths were observed with nivo (meningoencephalitis and pneumonitis). Most frequent grade ≥ 3 AEs were asthenia (7.3%), anaemia (6.3%) and alkaline phosphatase increased (5.8%).

Conclusions

Nivo+Ipi only reached the primary endpoint in 2nd/3rd line NECs pts with acceptable toxicity.

Clinical trial identification

EudraCT 2017-003863-37.

Editorial acknowledgement

Legal entity responsible for the study

Intergroupe Francophone de Cancérologie Thoracique.

Funding

BMS.

Disclosure

N. Girard: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Boehringer; Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Advisory Board: Lilly; Financial Interests, Personal, Advisory Board: Teva; Financial Interests, Personal, Advisory Board: Seagen; Financial Interests, Personal, Advisory Board: Takeda; Financial Interests, Personal, Advisory Board: Grunenthal; Financial Interests, Personal, Advisory Board: GSK; Financial Interests, Personal, Advisory Board: Lilly; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: AbbVie; Financial Interests, Personal, Advisory Board: Janssen; Financial Interests, Personal, Advisory Board: Sanofi; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Principal Investigator: Roche; Financial Interests, Personal, Principal Investigator: Boehringer; Financial Interests, Personal, Principal Investigator: AstraZeneca; Financial Interests, Personal, Principal Investigator: MSD; Financial Interests, Personal, Principal Investigator: BMS; Financial Interests, Personal, Principal Investigator: Seagen; Financial Interests, Personal, Principal Investigator: Janssen; Financial Interests, Personal, Principal Investigator: Lilly; Financial Interests, Personal, Writing Engagements: Edimark; Financial Interests, Personal, Writing Engagements: Fréquence médicale; Other, Personal, Other: AstraZeneca. J. Mazieres: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Daiichi; Financial Interests, Personal, Advisory Board: Pierre Fabre; Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Institutional, Research Grant: Pierre Fabre. H. Lena: Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Takeda; Non-Financial Interests, Institutional, Principal Investigator: BMS; Non-Financial Interests, Institutional, Principal Investigator: AstraZeneca; Non-Financial Interests, Institutional, Principal Investigator: Roche; Non-Financial Interests, Institutional, Principal Investigator: AbbVie; Non-Financial Interests, Institutional, Principal Investigator: GSK; Financial Interests, Personal, Advisory Board: Lilly; Non-Financial Interests, Institutional, Principal Investigator: Lilly; Non-Financial Interests, Institutional, Principal Investigator: Celgene; Non-Financial Interests, Institutional, Principal Investigator: Novartis; Financial Interests, Personal, Advisory Board: Pfizer; Non-Financial Interests, Institutional, Principal Investigator: Pfizer; Financial Interests, Personal, Advisory Board: Amgen; Non-Financial Interests, Institutional, Principal Investigator: Amgen; Non-Financial Interests, Institutional, Principal Investigator: Regeneron. C. Lepage: Financial Interests, Personal, Training: Bayer; Financial Interests, Personal, Training: Amgen; Financial Interests, Personal, Training: Ipsen; Financial Interests, Personal, Training: Pierre Fabre; Financial Interests, Personal, Other, Congress invitation: Novartis; Financial Interests, Personal, Other, Congress invitation: Merck; Financial Interests, Personal, Other, Congress invitation: Ipsen; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: ADVANCED ACCELERATOR APPLICATIONS (AAA). A. Madroszyk: Financial Interests, Personal, Other, Accomodation, lunch, transportation: BMS. P. Michel: Financial Interests, Personal, Advisory Board: Servier; Financial Interests, Personal, Advisory Board: BAYER; Financial Interests, Personal, Invited Speaker: MERCK. C. Louvet: Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Servier; Financial Interests, Personal, Advisory Board: Amgen. V. Westeel: Financial Interests, Personal, Other, Honoraria: AstraZeneca; Financial Interests, Personal, Other, Honoraria: BMS; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Takeda; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Institutional, Sponsor/Funding: Boehringer Ingelheim; Financial Interests, Institutional, Sponsor/Funding: MSD; Financial Interests, Personal, Other, Travel, accomodations, expenses: AstraZeneca; Financial Interests, Personal, Other, Travel, accomodations, expenses: BMS; Financial Interests, Personal, Other, Travel, accomodations, expenses: Pfizer; Financial Interests, Personal, Other, Travel, accomodations, expenses: Roche. T. Walter: Financial Interests, Personal, Advisory Board: Novartis - AAA; Non-Financial Interests, Personal, Funding: Ipsen; Non-Financial Interests, Institutional, Project Lead: Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings